Fig. 3From: A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes a Survival of subjects with IPSS-R lower-risk with micro-megakaryocyte <25 or ≥25 %; b survival of subjects with dysplastic mono-nucleated megakaryocytes <30 or ≥30 %Back to article page